Q-omics provides the consensus-scored KIF5C profile across patient tissues and cancer cell-line models. KIF5C expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, KIF5C is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, KIF5C RNA expression shows 20,220 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KICH, and GBM as cancer lineages where KIF5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF5C survival associations across molecular data types. KIF5C RNA expression shows survival associations in the most cancer types (18), followed by mutation status (10) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF5C RNA expression–survival associations across cancer types. High KIF5C expression shows unfavorable associations in KIRP, UVM, STAD and UCEC, but favorable associations in BRCA and PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for KIF5C RNA expression.
This table summarizes KIF5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF5C shows lower tumor expression in KICH, COAD, KIRP, KIRC and THCA and higher tumor expression in BRCA. The KICH box plot shows higher KIF5C RNA expression in normal versus tumor tissue (log2 FC = −1.902, t-test p < 0.001).
This table shows molecular features associated with KIF5C in patient tissues and cancer cell lines. In patient samples, KIF5C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
